Nanoscale Coordination Polymers Codeliver Chemotherapeutics and siRNAs to Eradicate Tumors of Cisplatin-Resistant Ovarian Cancer.
暂无分享,去创建一个
Christopher Poon | S. Yamada | Wenbin Lin | Chunbai He | Christina Chan | Chunbai He | Wenbin Lin | S Diane Yamada | Christina Chan | Christopher Poon
[1] A. Tinker,et al. "Platinum resistant" ovarian cancer: what is it, who to treat and how to measure benefit? , 2014, Gynecologic oncology.
[2] Gang Zheng,et al. Nanoparticle-enabled, image-guided treatment planning of target specific RNAi therapeutics in an orthotopic prostate cancer model. , 2014, Small.
[3] B. Monk,et al. Latest research and treatment of advanced-stage epithelial ovarian cancer , 2013, Nature Reviews Clinical Oncology.
[4] P. Krammer,et al. Tumor Immunology , 2018, Medical Immunology.
[5] P B Laub,et al. Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells , 2005, British Journal of Cancer.
[6] Enzo Di Fabrizio,et al. Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy , 2012, International journal of nanomedicine.
[7] U. Menon,et al. Ovarian cancer screening—Current status, future directions☆ , 2014, Gynecologic oncology.
[8] Leaf Huang,et al. Non-viral nanocarriers for siRNA delivery in breast cancer. , 2014, Journal of controlled release : official journal of the Controlled Release Society.
[9] Michael S. Goldberg,et al. Cosilencing of PKM-2 and MDR-1 Sensitizes Multidrug-Resistant Ovarian Cancer Cells to Paclitaxel in a Murine Model of Ovarian Cancer , 2015, Molecular Cancer Therapeutics.
[10] Alexander V Kabanov,et al. Nanocarriers for delivery of platinum anticancer drugs. , 2013, Advanced drug delivery reviews.
[11] K. Ushijima. Treatment for Recurrent Ovarian Cancer—At First Relapse , 2009, Journal of oncology.
[12] M. Eblan,et al. Clinical Translation of Nanomedicine. , 2015, Chemical reviews.
[13] Lily Yang,et al. Targeted delivery of siRNA-generating DNA nanocassettes using multifunctional nanoparticles. , 2013, Small.
[14] S. Inoue,et al. Curcumin Targeted, Polymalic Acid-Based MRI Contrast Agent for the Detection of Aβ Plaques in Alzheimer's Disease. , 2015, Macromolecular bioscience.
[15] Z. Duan,et al. MDR1 siRNA loaded hyaluronic acid-based CD44 targeted nanoparticle systems circumvent paclitaxel resistance in ovarian cancer , 2015, Scientific Reports.
[16] Warren C W Chan,et al. Strategies for the intracellular delivery of nanoparticles. , 2011, Chemical Society reviews.
[17] Gert Storm,et al. Endosomal escape pathways for delivery of biologicals. , 2011, Journal of controlled release : official journal of the Controlled Release Society.
[18] G. Mills,et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth , 2011, Nature Medicine.
[19] Kenneth P. Nephew,et al. Rethinking ovarian cancer: recommendations for improving outcomes , 2011, Nature Reviews Cancer.
[20] Gang Zheng,et al. Cancer nanomedicine: addressing the dark side of the enhanced permeability and retention effect. , 2015, Nanomedicine.
[21] Chad A. Mirkin,et al. Gene regulation with polyvalent siRNA-nanoparticle conjugates. , 2009, Journal of the American Chemical Society.
[22] Taeghwan Hyeon,et al. Multifunctional tumor pH-sensitive self-assembled nanoparticles for bimodal imaging and treatment of resistant heterogeneous tumors. , 2014, Journal of the American Chemical Society.
[23] Lily Yang,et al. Targeted Delivery with Imaging Assessment of siRNA Expressing Nanocassettes into Cancer. , 2016, Methods in molecular biology.
[24] Wenbin Lin,et al. Self-assembled core-shell nanoparticles for combined chemotherapy and photodynamic therapy of resistant head and neck cancers. , 2015, ACS nano.
[25] Sarah Seifert,et al. Image-based analysis of lipid nanoparticle–mediated siRNA delivery, intracellular trafficking and endosomal escape , 2013, Nature Biotechnology.
[26] Chad A. Mirkin,et al. Spherical Nucleic Acid Nanoparticle Conjugates as an RNAi-Based Therapy for Glioblastoma , 2013, Science Translational Medicine.
[27] L. Kèlland,et al. The resurgence of platinum-based cancer chemotherapy , 2007, Nature Reviews Cancer.
[28] H. Hollema,et al. Cell biological markers of drug resistance in ovarian carcinoma. , 1995, Gynecologic oncology.
[29] M. Gottesman. Mechanisms of cancer drug resistance. , 2002, Annual review of medicine.
[30] Leaf Huang,et al. Pharmacokinetics and biodistribution of nanoparticles. , 2008, Molecular pharmaceutics.
[31] Warren C W Chan,et al. The effect of nanoparticle size, shape, and surface chemistry on biological systems. , 2012, Annual review of biomedical engineering.
[32] Joseph M. DeSimone,et al. Strategies in the design of nanoparticles for therapeutic applications , 2010, Nature Reviews Drug Discovery.
[33] F. Muggia. Platinum compounds 30 years after the introduction of cisplatin: implications for the treatment of ovarian cancer. , 2009, Gynecologic oncology.
[34] R. Mach,et al. Using SV119‐Gold Nanocage Conjugates to Eradicate Cancer Stem Cells Through a Combination of Photothermal and Chemo Therapies , 2014, Advanced healthcare materials.
[35] Taeghwan Hyeon,et al. pH-sensitive nanoformulated triptolide as a targeted therapeutic strategy for hepatocellular carcinoma. , 2014, ACS nano.
[36] George A. Calin,et al. RNA interference in the clinic: challenges and future directions , 2011, Nature Reviews Cancer.
[37] William Y. Kim,et al. Nanoparticle modulation of the tumor microenvironment enhances therapeutic efficacy of cisplatin. , 2015, Journal of controlled release : official journal of the Controlled Release Society.
[38] Wenbin Lin,et al. Self-assembled nanoscale coordination polymers carrying siRNAs and cisplatin for effective treatment of resistant ovarian cancer. , 2015, Biomaterials.
[39] John J. Rossi,et al. The promises and pitfalls of RNA-interference-based therapeutics , 2009, Nature.
[40] Christopher Poon,et al. Self-assembled nanoscale coordination polymers with trigger release properties for effective anticancer therapy , 2014, Nature Communications.
[41] R. Agarwal,et al. Ovarian cancer: strategies for overcoming resistance to chemotherapy , 2003, Nature Reviews Cancer.
[42] A. Fire,et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans , 1998, Nature.
[43] Mark E. Davis,et al. Nanoparticle therapeutics: an emerging treatment modality for cancer , 2008, Nature Reviews Drug Discovery.
[44] Bulent Ozpolat,et al. Preclinical and clinical development of siRNA-based therapeutics. , 2015, Advanced drug delivery reviews.
[45] J. Ljubimova,et al. Nanomedicine therapeutic approaches to overcome cancer drug resistance. , 2013, Advanced drug delivery reviews.
[46] D. Dykxhoorn,et al. Breaking down the barriers: siRNA delivery and endosome escape , 2010, Journal of Cell Science.
[47] P. Kruk,et al. The genesis of RNA interference, its potential clinical applications, and implications in gynecologic cancer. , 2005, Gynecologic oncology.
[48] E. Wang,et al. Nanoparticle delivery of chemosensitizers improve chemotherapy efficacy without incurring additional toxicity. , 2015, Nanoscale.
[49] A. Malpica,et al. Ovarian low-grade serous carcinoma: a comprehensive update. , 2012, Gynecologic oncology.